VALN - Valneva suspended from marketing chikungunya shot in U.S. over safety concerns
2025-08-23 07:04:09 ET
More on Valneva
- Valneva SE 2025 Q2 - Results - Earnings Call Presentation
- Valneva SE (VALN) Q2 2025 Earnings Call Transcript
- Valneva reports 1H results; reaffirms FY outlook
- FDA lifts pause on Valneva's chikungunya vaccine in elderly
- Seeking Alpha’s Quant Rating on Valneva